ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23.5 TWD -0.63% Market Closed
Market Cap: 18.6B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ScinoPharm Taiwan Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Net Issuance of Debt
-NT$85.1m
CAGR 3-Years
29%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Y
YungShin Global Holding Corp
TWSE:3705
Net Issuance of Debt
-NT$328.9m
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formosa Laboratories Inc
TWSE:4746
Net Issuance of Debt
-NT$320.1m
CAGR 3-Years
-92%
CAGR 5-Years
N/A
CAGR 10-Years
-2%
S
SCI Pharmtech Inc
TWSE:4119
Net Issuance of Debt
NT$427.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
11%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Net Issuance of Debt
-NT$731.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
6%
Standard Chem & Pharm Co Ltd
TWSE:1720
Net Issuance of Debt
-NT$651.6m
CAGR 3-Years
-201%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
18.6B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
16.51 TWD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is ScinoPharm Taiwan Ltd's Net Issuance of Debt?
Net Issuance of Debt
-85.1m TWD

Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Net Issuance of Debt amounts to -85.1m TWD.

What is ScinoPharm Taiwan Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
26%

The average annual Net Issuance of Debt growth rates for ScinoPharm Taiwan Ltd have been 29% over the past three years , 26% over the past five years .

Back to Top